Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
TTLC 2020
Targeted Therapies in Lung Cancer 2020
Access to all slides from presentations that occur during the IASLC 2020 Targeted Therapies of Lung Cancer Meeting in Santa Monica, CA
Presentation Date(s):- February 19 – 22, 2020
- Total Presentations: 230
-
+
S07 - Stage 3 NSCLC/Combined Modality Therapy
- Type: General Session
- Track:
- Presentations: 11
- Slides Available
- Coordinates: 2/21/2020, 08:50 - 09:55,
-
+
PACIFIC Trials (Slides Available)
08:50 - 08:55 | Author(s): Everett Vokes
- Abstract
No abstract available for this presentation
-
+
Chemo-RT plus Pembrolizumab (Slides Available)
08:55 - 09:00 | Author(s): Greg Durm
- Abstract
No abstract available for this presentation
-
+
ECOG-ACRIN 5181 (Chemo-RT plus Durva) (Slides Available)
09:00 - 09:05 | Author(s): Nathan Pennell
- Abstract
No abstract available for this presentation
-
+
RT + Atezolizumab (Slides Available)
09:05 - 09:10 | Author(s): Christine Bestvina
- Abstract
No abstract available for this presentation
-
+
RT plus Durva for high PD-L1 Exp NSCLC NRG LU004 (Slides Available)
09:10 - 09:15 | Author(s): Steven Lin
- Abstract
No abstract available for this presentation
-
+
Chemo RT plus PARP inhibition (Slides Available)
09:15 - 09:20 | Author(s): Primo Lara
- Abstract
No abstract available for this presentation
-
+
Chemo RT + Metformin
09:20 - 09:25 | Author(s): Theodoros Tsakiridis
- Abstract
No abstract available for this presentation
-
+
Chemo RT followed by Targeted Therapy: LAURA Study (Slides Available)
09:25 - 09:30 | Author(s): Suresh Ramalingam
- Abstract
No abstract available for this presentation
-
+
RTOG 1308: Proton Vs. Photon (Slides Available)
09:30 - 09:35 | Author(s): Jeffrey Bradley
- Abstract
No abstract available for this presentation
-
+
RT for oligometastatic NSCLC (NRG LU002) (Slides Available)
09:35 - 09:40 | Author(s): Kristin Higgins
- Abstract
No abstract available for this presentation
-
+
SBRT + Immunotherapy (Slides Available)
09:40 - 09:45 | Author(s): Roy Decker
- Abstract
No abstract available for this presentation
-
+
D04 - Should RT be given for a patient responding to IO for oligometastatic NSCLC?
- Type: General Session
- Track:
- Presentations: 2
- Slides Available
- Coordinates: 2/21/2020, 10:15 - 10:35,
-
+
Yes (Slides Available)
10:15 - 10:25 | Author(s): Puneeth Iyengar
- Abstract
No abstract available for this presentation
-
+
No
10:25 - 10:35 | Author(s): Walter Curran Jr.
- Abstract
No abstract available for this presentation
-
+
S08 - Antibody Drug Conjugates
- Type: General Session
- Track:
- Presentations: 11
- Slides Available
- Coordinates: 2/21/2020, 10:35 - 11:35,
-
+
Science (Slides Available)
10:35 - 10:45 | Author(s): Pasi Janne
- Abstract
No abstract available for this presentation
-
+
DS-1062 (Trop-2) (Slides Available)
10:45 - 10:50 | Author(s): Jacob Sands
- Abstract
No abstract available for this presentation
-
+
DS1205 (AXL) (Slides Available)
10:50 - 10:55 | Author(s): Helena Yu
- Abstract
No abstract available for this presentation
-
+
IMMUNO132 (Trop-2) (Slides Available)
10:55 - 11:00 | Author(s): Ross Camidge
- Abstract
No abstract available for this presentation
-
+
Enapotamab Vedotin (Slides Available)
11:00 - 11:05 | Author(s): Hossein Borghaei
- Abstract
No abstract available for this presentation
-
+
ABBV399 (MET) (Slides Available)
11:05 - 11:10 | Author(s): Jyoti Patel
- Abstract
No abstract available for this presentation
-
+
DS8201 (HER2) (Slides Available)
11:10 - 11:15 | Author(s): Jose Pacheco
- Abstract
No abstract available for this presentation
-
+
ADCT502 (HER2) (Slides Available)
11:15 - 11:20 | Author(s): Grace Dy
- Abstract
No abstract available for this presentation
-
+
BGB324 (AXL TKI) (Slides Available)
11:20 - 11:25 | Author(s): David Gerber
- Abstract
No abstract available for this presentation
-
+
U3-1402 (HER3-directed ADC) (Slides Available)
11:25 - 11:30 | Author(s): Conor Steuer
- Abstract
No abstract available for this presentation
-
+
XMT1536 (NaPi2b) (Slides Available)
11:30 - 11:35 | Author(s): Melissa Johnson
- Abstract
No abstract available for this presentation
-
+
S09 - FGFR/PDFGR/Angiogenesis/VEGF
- Type: General Session
- Track:
- Presentations: 8
- Slides Available
- Coordinates: 2/21/2020, 11:45 - 12:40,
-
+
Science (Slides Available)
11:45 - 11:55 | Author(s): John Heymach
- Abstract
No abstract available for this presentation
-
+
Nivolumab + vorolanib (Slides Available)
11:55 - 12:00 | Author(s): Heather Wakelee
- Abstract
No abstract available for this presentation
-
+
Nivolumab + sitravantinib (Slides Available)
12:00 - 12:05 | Author(s): Kai He
- Abstract
No abstract available for this presentation
-
+
EGFR + Bevacizumab or Ramicurumab (Slides Available)
12:05 - 12:10 | Author(s): Balazs Halmos
- Abstract
No abstract available for this presentation
-
+
Ramacirumab + IO (Slides Available)
12:10 - 12:15 | Author(s): Rathi Pillai
- Abstract
No abstract available for this presentation
-
+
Cabozantinib (Slides Available)
12:15 - 12:20 | Author(s): Heather Wakelee
- Abstract
No abstract available for this presentation
-
+
Nintedanib + IO (Slides Available)
12:20 - 12:25 | Author(s): Erin Schenk
- Abstract
No abstract available for this presentation
-
+
Nintedanib for mutations and its receptors
12:25 - 12:30 | Author(s): Ticiana Leal
- Abstract
No abstract available for this presentation
-
+
OA - Best Abstracts - Oral Presentations
- Type: General Session
- Track:
- Presentations: 5
- Slides Available
- Coordinates: 2/21/2020, 13:40 - 14:40,
-
+
Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer (Slides Available)
13:40 - 13:48 | Author(s): Biagio Ricciuti
- Abstract
No abstract available for this presentation
-
+
Interferon Gamma Resistance in Setting of LKB1 Loss: Phenotypic Characterization and Investigation of Mechanism (Slides Available)
13:48 - 13:56 | Author(s): Jacob Kaufman
- Abstract
No abstract available for this presentation
-
+
Detection of NRG1 gene fusions in NSCLC (Slides Available)
13:56 - 14:04 | Author(s): Sushma Jonna
- Abstract
No abstract available for this presentation
-
+
Targeting inflammatory monocytes with dual CCR2/5 inhibition in combination with immune checkpoint inhibition in lung squamous carcinoma (Slides Available)
14:04 - 14:12 | Author(s): Yvonne Chao
- Abstract
No abstract available for this presentation
-
+
MSK-ACCESS for non-invasive somatic mutation profiling of lung cancers utilizing circulating tumor DNA: A prospective clinical study
14:12 - 14:20 | Author(s): Emily Lebow
- Abstract
No abstract available for this presentation
-
+
S10 - ROS1, TRK, ALK, NRG Fusions
- Type: General Session
- Track:
- Presentations: 14
- Slides Available
- Coordinates: 2/21/2020, 14:40 - 16:05,
-
+
Science
14:40 - 14:50 | Author(s): Alexander Drilon
- Abstract
No abstract available for this presentation
-
+
Entrectinib (Slides Available)
14:50 - 14:55 | Author(s): Robert Doebele
- Abstract
No abstract available for this presentation
-
+
Repotrectinib (Slides Available)
14:55 - 15:00 | Author(s): Sai-Hong Ou
- Abstract
No abstract available for this presentation
-
+
Crizotinib (Slides Available)
15:00 - 15:05 | Author(s): Jessica Lin
- Abstract
No abstract available for this presentation
-
+
Lorlatinib (Slides Available)
15:05 - 15:10 | Author(s): Christine Lovly
- Abstract
No abstract available for this presentation
-
+
DS6051b (Slides Available)
15:10 - 15:15 | Author(s): Elaine Shum
- Abstract
No abstract available for this presentation
-
+
Ceritinib +/- Trametinib (Slides Available)
15:15 - 15:20 | Author(s): Caroline McCoach
- Abstract
No abstract available for this presentation
-
+
Larotrectinib (Slides Available)
15:20 - 15:25 | Author(s): Anna Farago
- Abstract
No abstract available for this presentation
-
+
Loxo 195
15:25 - 15:30 | Author(s): Alexander Drilon
- Abstract
No abstract available for this presentation
-
+
Ensartinib (Slides Available)
15:30 - 15:35 | Author(s): Leora Horn
- Abstract
No abstract available for this presentation
-
+
Brigatinib (Slides Available)
15:35 - 15:40 | Author(s): Thomas Stinchcombe
- Abstract
No abstract available for this presentation
-
+
Alectinib + bev or other (Slides Available)
15:40 - 15:45 | Author(s): Justin Gainor
- Abstract
No abstract available for this presentation
-
+
IO post TKI (Slides Available)
15:45 - 15:50 | Author(s): Corey Langer
- Abstract
No abstract available for this presentation
-
+
NRG1 fusion Inhibitors (Slides Available)
15:50 - 15:55 | Author(s): Stephen Liu
- Abstract
No abstract available for this presentation
-
+
S11 - RET/MET Inhibitors
- Type: General Session
- Track:
- Presentations: 14
- Slides Available
- Coordinates: 2/21/2020, 16:25 - 17:50,
-
+
Science (Slides Available)
16:25 - 16:35 | Author(s): Robert Doebele
- Abstract
No abstract available for this presentation
-
+
BLU667 (RET) (Slides Available)
16:35 - 16:40 | Author(s): Justin Gainor
- Abstract
No abstract available for this presentation
-
+
Loxo292 selpercatinib (RET) (Slides Available)
16:40 - 16:45 | Author(s): Alexander Drilon
- Abstract
No abstract available for this presentation
-
+
TPX-0046 (RET) (Slides Available)
16:45 - 16:50 | Author(s): Misako Nagasaka
- Abstract
No abstract available for this presentation
-
+
RXDX105 (Slides Available)
16:50 - 16:55 | Author(s): Antoinette Wozniak
- Abstract
No abstract available for this presentation
-
+
Crizotinib (MET) (Slides Available)
16:55 - 17:00 | Author(s): Mark Kris
- Abstract
No abstract available for this presentation
-
+
Savolitinib (MET) (Slides Available)
17:00 - 17:05 | Author(s): Mark Awad
- Abstract
No abstract available for this presentation
-
+
Topotinib (MET) (Slides Available)
17:05 - 17:10 | Author(s): Xiuning Le
- Abstract
No abstract available for this presentation
-
+
Capmatinib (MET) (Slides Available)
17:10 - 17:15 | Author(s): Rebecca Heist
- Abstract
No abstract available for this presentation
-
+
TPX0022 (MET/CSFR1/SRC) (Slides Available)
17:15 - 17:20 | Author(s): Sandip Patel
- Abstract
No abstract available for this presentation
-
+
APL-101 (Slides Available)
17:20 - 17:25 | Author(s): Aaron Mansfield
- Abstract
No abstract available for this presentation
-
+
Merestinib (Slides Available)
17:25 - 17:30 | Author(s): Julia Rotow
- Abstract
No abstract available for this presentation
-
+
REGN 5093 (Slides Available)
17:30 - 17:35 | Author(s): Thomas Marron
- Abstract
No abstract available for this presentation
-
+
Sym015 (MET) (Slides Available)
17:35 - 17:40 | Author(s): Ross Camidge
- Abstract
No abstract available for this presentation
-
+
S12 - Mesothelioma
- Type: General Session
- Track:
- Presentations: 6
- Slides Available
- Coordinates: 2/21/2020, 16:25 - 17:50,
-
+
Science (Slides Available)
17:50 - 18:00 | Author(s): Harvey Pass
- Abstract
No abstract available for this presentation
-
+
Brentuximab (Slides Available)
18:00 - 18:05 | Author(s): Anne Tsao
- Abstract
No abstract available for this presentation
-
+
Anetumab Ravtansine + Pembrolizumab (Slides Available)
18:05 - 18:10 | Author(s): Kaushal Parikh
- Abstract
No abstract available for this presentation
-
+
WT1 Peptide Vaccine and CAR (Slides Available)
18:10 - 18:15 | Author(s): Matthew Gubens
- Abstract
No abstract available for this presentation
-
+
Chemo + IO (Slides Available)
18:15 - 18:20 | Author(s): Patrick Forde
- Abstract
No abstract available for this presentation
-
+
Neoadjuvant chemo-IO (Slides Available)
18:20 - 18:25 | Author(s): Anne Tsao
- Abstract
No abstract available for this presentation
-
+
S13 - Immunotherapy Combinations
- Type: General Session
- Track:
- Presentations: 24
- Slides Available
- Coordinates: 2/22/2020, 07:00 - 09:15,
-
+
Science (Slides Available)
07:00 - 07:10 | Author(s): Edward Garon
- Abstract
No abstract available for this presentation
-
+
CTLA4 combinations (Slides Available)
07:10 - 07:15 | Author(s): Jarushka Naidoo
- Abstract
No abstract available for this presentation
-
+
PD1 and ICOS (Slides Available)
07:15 - 07:20 | Author(s): Charu Aggarwal
- Abstract
No abstract available for this presentation
-
+
IO + LAG3 (Slides Available)
07:20 - 07:25 | Author(s): Ashwin Somasundaram
- Abstract
No abstract available for this presentation
-
+
IO + CD137 (Slides Available)
07:25 - 07:30 | Author(s): Adrian Sacher
- Abstract
No abstract available for this presentation
-
+
IO + CDX1140 (anti-CD40) (Slides Available)
07:30 - 07:35 | Author(s): Rachel Sanborn
- Abstract
No abstract available for this presentation
-
+
IO + OX40 (Slides Available)
07:35 - 07:40 | Author(s): Narjust Duma
- Abstract
No abstract available for this presentation
-
+
LYC44716 (Slides Available)
07:40 - 07:45 | Author(s): Scott Gettinger
- Abstract
No abstract available for this presentation
-
+
Pembrolizumab + vorinostat (Slides Available)
07:45 - 07:50 | Author(s): Ben Creelan
- Abstract
No abstract available for this presentation
-
+
IO+ Epacadostat (Slides Available)
07:50 - 07:55 | Author(s): Liza Villaruz
- Abstract
No abstract available for this presentation
-
+
Pembrolizumab and itacitinib (JAK1) (Slides Available)
07:55 - 08:00 | Author(s): Joshua Bauml
- Abstract
No abstract available for this presentation
-
+
Atezolizumab + Cobimetinib (Slides Available)
08:00 - 08:05 | Author(s): Ryan Gentzler
- Abstract
No abstract available for this presentation
-
+
MGA271 (Slides Available)
08:05 - 08:10 | Author(s): Konstantinos Leventakos
- Abstract
No abstract available for this presentation
-
+
Phase I Study of TJ004309 (anti-CD73) in combination with atezolizumab in advanced cancers (Slides Available)
08:10 - 08:15 | Author(s): Francisco Robert
- Abstract
No abstract available for this presentation
-
+
TRQ15-01 (Slides Available)
08:15 - 08:20 | Author(s): Melissa Johnson
- Abstract
No abstract available for this presentation
-
+
IO + CCR2/5 Inhibitors (Slides Available)
08:20 - 08:25 | Author(s): Chad Pecot
- Abstract
No abstract available for this presentation
-
+
Siglec 15 (Slides Available)
08:25 - 08:30 | Author(s): Roy Herbst
- Abstract
No abstract available for this presentation
-
+
CB 839
08:30 - 08:35 | Author(s): Aaron Lisberg
- Abstract
No abstract available for this presentation
-
+
Pinabulin (Slides Available)
08:35 - 08:40 | Author(s): Lyudmila Bazhenova
- Abstract
No abstract available for this presentation
-
+
Monalizumab (Slides Available)
08:40 - 08:45 | Author(s): Joshua Reuss
- Abstract
No abstract available for this presentation
-
+
Comparing effect of IO combinations (Slides Available)
08:45 - 08:50 | Author(s): Jack Lee
- Abstract
No abstract available for this presentation
-
+
Afatinib + Pembro (Slides Available)
08:50 - 08:55 | Author(s): Benjamin Levy
- Abstract
No abstract available for this presentation
-
+
IO + GSK3377794 (Slides Available)
08:55 - 09:00 | Author(s): Ronan Kelly
- Abstract
No abstract available for this presentation
-
+
PY314 anti-TREM2 antibody
09:00 - 09:05 | Author(s): Erin Schenk
- Abstract
No abstract available for this presentation
-
+
S14 - mTOR/PI3K/CDK/DNA repair/CHK1/Wee1/PARP inhibition
- Type: General Session
- Track:
- Presentations: 21
- Slides Available
- Coordinates: 2/22/2020, 09:30 - 11:25,
-
+
Rucaparib (Slides Available)
09:30 - 09:35 | Author(s): Shirish Gadgeel
- Abstract
No abstract available for this presentation
-
+
Prexasertib (Slides Available)
09:35 - 09:40 | Author(s): Stephen Liu
- Abstract
No abstract available for this presentation
-
+
TAK228 (Sapanisertib) (Slides Available)
09:40 - 09:45 | Author(s): Jonathan Riess
- Abstract
No abstract available for this presentation
-
+
Taselisib (Slides Available)
09:45 - 09:50 | Author(s): Corey Langer
- Abstract
No abstract available for this presentation
-
+
Gedatolisib (Slides Available)
09:50 - 09:55 | Author(s): Zofia Piotrowska
- Abstract
No abstract available for this presentation
-
+
ABTL 0812 (Slides Available)
09:55 - 10:00 | Author(s): George Blumenschein
- Abstract
No abstract available for this presentation
-
+
mTOR inhibition +PD-1 inhibition (Slides Available)
10:00 - 10:05 | Author(s): Fadlo Khuri
- Abstract
No abstract available for this presentation
-
+
PI3K inhibition + PD-1 inhibition (Slides Available)
10:05 - 10:10 | Author(s): Jennifer Carlisle
- Abstract
No abstract available for this presentation
-
+
Sapanisertib + CB-839 (Slides Available)
10:10 - 10:15 | Author(s): Jonathan Riess
- Abstract
No abstract available for this presentation
-
+
Sirolimus + Auranofin (Slides Available)
10:15 - 10:20 | Author(s): Helen Ross
- Abstract
No abstract available for this presentation
-
+
Trilaciclib (Slides Available)
10:20 - 10:25 | Author(s): Jeffrey Crawford
- Abstract
No abstract available for this presentation
-
+
MK 8628 & GSK 525762 (Slides Available)
10:25 - 10:30 | Author(s): Taofeek Owonikoko
- Abstract
No abstract available for this presentation
-
+
Olaparib (Slides Available)
10:30 - 10:35 | Author(s): Ben Creelan
- Abstract
No abstract available for this presentation
-
+
Talazoparib (Slides Available)
10:35 - 10:40 | Author(s): Taofeek Owonikoko
- Abstract
No abstract available for this presentation
-
+
Niraparib (Slides Available)
10:40 - 10:45 | Author(s): Zofia Piotrowska
- Abstract
No abstract available for this presentation
-
+
VX-970 (Slides Available)
10:45 - 10:50 | Author(s): Deborah Doroshow
- Abstract
No abstract available for this presentation
-
+
AZD 6738 (Slides Available)
10:50 - 10:55 | Author(s): Daniel Morgensztern
- Abstract
No abstract available for this presentation
-
+
BAY 1895344 (Slides Available)
10:55 - 11:00 | Author(s): Timothy Yap
- Abstract
No abstract available for this presentation
-
+
Adavosertib (AZD1775) (Slides Available)
11:00 - 11:05 | Author(s): Dwight Owen
- Abstract
No abstract available for this presentation
-
+
AZD 0156 (Slides Available)
11:05 - 11:10 | Author(s): Patricia LoRusso
- Abstract
No abstract available for this presentation
-
+
DNA PK inhibition (Slides Available)
11:10 - 11:15 | Author(s): George Simon
- Abstract
No abstract available for this presentation